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Oncogenic RAS mutants confer
resistance of RMS13
rhabdomyosarcoma cells to oxidative
stress-induced ferroptotic cell death
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1 Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany, 2 German Cancer Consortium
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University Medical Center, Göttingen, Germany
Recent genomic studies revealed a high rate of recurrent mutations in the RAS pathway in
primary rhabdomyosarcoma (RMS) samples. In the present study, we therefore investi-
gated how oncogenic RAS mutants impinge on the regulation of cell death of RMS13
cells. Here, we report that ectopic expression of NRAS12V, KRAS12V, or HRAS12V
protects RMS13 cells from oxidative stress-induced cell death. RMS13 cells engineered
to express NRAS12V, KRAS12V, or HRAS12V were significantly less susceptible to
loss of cell viability upon treatment with several oxidative stress inducers including the
thioredoxin reductase inhibitor Auranofin, the glutathione (GSH) peroxidase 4 inhibitor
RSL3 or Erastin, an inhibitor of the cysteine/glutamate amino acid transporter system
xc  that blocks GSH synthesis. Notably, addition of Ferrostatin-1 confers protection
against Erastin- or RSL3-induced cytotoxicity, indicating that these compounds trigger
ferroptosis, an iron-dependent form of programed cell death. Furthermore, RMS13 cells
overexpressing oncogenic RAS mutants are significantly protected against the dual
PI3K/mTOR inhibitor PI103, whereas they are similarly sensitive to DNA-damaging drugs
such as Doxorubicin or Etoposide. This suggests that oncogenic RAS selectively mod-
ulates cell death pathways triggered by cytotoxic stimuli in RMS13 cells. In conclusion,
our discovery of an increased resistance to oxidative stress imposed by oncogenic RAS
mutants in RMS13 cells has important implications for the development of targeted
therapies for RMS.
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Introduction
Rhabdomyosarcoma is the most common soft-tissue sarcoma in childhood and adolescence and
can be divided into two major histopathologies, i.e., alveolar (ARMS) and embryonal (ERMS)
(1, 2). Recent data obtained from two next-generation sequencing (NGS) studies revealed that
RMS harbor a high rate of recurrent mutations in the RAS pathway (3, 4).Whole-genome and
whole-exome sequencing of 147 tumor/normal pairs showed recurrent alterations in the RAS genes
predominantly in the ERMS subtype, i.e., NRAS in 11.7%, KRAS in 6.4%, andHRAS in 4.3% of cases
(4). In an independent study, genomic analysis of 13 primary RMS samples and matched normal
tissue revealed that the most common cancer consensus gene mutations in RMS were in the RAS
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pathway, including mutations in NRAS, KRAS, and HRAS (3).
In this study, 75% (6/8) of high-risk ERMS tumors harbored
RAS pathway mutations and these mutations were significantly
associatedwith risk-group assignment (3). Additional studies doc-
umented activation of the RAS pathway by oncogenic mutations
in HRAS, KRAS, or NRAS in RMS, i.e., in 42% [12/26] of RMS
(5) and in 35% (5/14), 22% (7/31) (6, 7), and 11.7% (8) of ERMS
tumors.
RAS proteins constitute key components of cellular signaling
pathways originating from cell surface receptors (9). Oncogenic
RAS proteins control a complex molecular network including
cell survival as well as cell death pathways (9). Also, oncogenic
RAS has been implicated in regulating the sensitivity of cancer
cells to oxidative stress (10). Depending on the cellular context,
e.g., on the sensitivity toward apoptotic stimuli and the status
of RAS effector pathways, oncogenic RAS proteins may exert
antiapoptotic and proapoptotic functions (9).
Despite the documented relevance of oncogenic RAS to drive
tumorigenesis of RMS, little is yet known about the impact on
cell death and survival signaling pathways. In the present study,
we therefore investigated the role of oncogenic RAS genes in the
control of cell death of RMS.
Materials and Methods
Cell Culture and Chemicals
RMS13 cells were obtained from the American Type Cul-
ture Collection (Manassas, VA, USA) and maintained in RPMI
1640 medium (Life Technologies, Eggenstein, Germany), sup-
plemented with 10% fetal calf serum (FCS) (Biochrom, Berlin,
Germany), 1mM glutamine, and 1% penicillin/streptomycin
(Invitrogen, Karlsruhe, Germany). PI3K/mTOR inhibitor PI103
(11) was purchased fromMerckMillipore (Darmstadt, Germany),
RSL3 from InterBIOScreen Ltd. (Moscow, Russia), Auranofin
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). All
chemicals were purchased from Sigma (Deisenhofen, Germany)
unless indicated otherwise.
Transduction
For overexpression of RASmutants, RMS13 cells were transduced
with pMSCV-puro vector containing oncogenic RAS mutants
(i.e., NRAS12V, KRAS12V, or HRAS12V; respective vectors were
sequenced to verify the identity of the individual mutant RAS) or
empty vector using the packaging cell line Platinum-E. Stable cell
lines were selected with puromycin.
Determination of Cell Viability, Cell Density,
Cell Count, Colony Formation, Apoptosis,
and Cell Death
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay according to the
manufacturer’s instructions (Roche Diagnostics, Mannheim, Ger-
many). Cell density was assessed by crystal violet staining (0.75%
crystal violet, 50% ethanol, 0.25% NaCl, 1.57% formaldehyde).
Crystal violet dye was resolubilized in 1% sodium dodecyl sulfate
(SDS) and absorbance at 550 nM was measured by microplate
reader (Infinite M200, Tecan Group Ltd., Maennedorf, Switzer-
land). Cell counts were determined by CASY cell counter (OLS
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FIGURE 1 | Effects of oncogenic RAS genes on RAS/MEK/ERK and
PI3K/AKT/mTOR signaling of RMS13 cells. RMS13 cells expressing
empty vector (EV), HRAS12V, KRAS12V, or NRAS12V were analyzed for RAS
protein expression using a pan-RAS antibody (A), for expression and
phosphorylation of ERK (B), and for expression and phosphorylation of AKT
and S6 ribosomal protein (C) by Western blotting. Representative blots are
shown.
OMNI Life Science, Bremen, Germany). Apoptosis was deter-
mined by analysis of DNA fragmentation of propidium iodide
(PI)-stained nuclei using flow cytometry (FACSCanto II, BD
Biosciences, Heidelberg, Germany), as described previously (12).
Cell death was assessed by measuring loss of plasma membrane
integrity by PI-emitted fluorescence and flow cytometry. For
colony assay, cells were seeded as single cells (200 cells/well) in six-
well plates and cultured for 10 days before colonies were stained
with crystal violet (Roth, Karlsruhe, Germany) and counted.
Western Blot Analysis
Western blot analysis was performed as described previously
(12) using the following antibodies: mouse anti-AKT (BD
Biosciences), rabbit anti-pAKT, rabbit anti-p4E-BP1, rabbit
anti-4E-BP1, rabbit anti-pS6, mouse anti-S6, rabbit anti-pERK,
rabbit anti-ERK, rabbit anti-pan-RAS (Cell Signaling, Beverly,
MA, USA). Mouse anti-GAPDH (HyTest, Turku, Finland) or
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FIGURE 2 | Effects of oncogenic RAS genes on cell numbers and
clonogenic growth of RMS13 cells. RMS13 cells expressing EV, HRAS12V,
KRAS12V, or NRAS12V were incubated for 48 h and analyzed for cell counts
(A), cell viability using MTT assay (B), and cell density using crystal violet assay
(C); results are expressed as percentage of cells expressing EV. Clonogenic
survival was assessed by colony formation assay at day 10 (D). The number of
colonies was counted after crystal violet staining and is expressed as
percentage of cells expressing EV [(D), left panel]; representative images are
shown [(D), right panel]. Mean+SD of three independent experiments
performed in triplicate are shown; *p<0.05; **p<0.01; ***p<0.001.
mouse anti-β-Actin (Sigma) were used as loading controls. Goat
anti-mouse IgG, donkey anti-goat IgG, goat anti-rabbit IgG conju-
gated to horseradish peroxidase (Santa Cruz Biotechnology Inc.),
and goat anti-mouse IgG1 or goat anti-mouse IgG2b (Southern
Biotech, Birmingham, AL, USA) conjugated to horseradish per-
oxidase were used as secondary antibodies. Enhanced chemilumi-
nescence was used for detection (AmershamBioscience, Freiburg,
Germany). Also, donkey anti-mouse IgG or donkey anti-rabbit
(LI-COR Biotechnology, Bad Homburg, Germany) labeled with
IRDye infrared dyes were used for detection. Representative blots
of at least two independent experiments are shown.
Statistical Analysis
Statistical significance was assessed by Student’s t-test (two-tailed
distribution, two-sample, unequal variance).
Results
Effects of Oncogenic RAS Genes on
RAS/MEK/ERK and PI3K/AKT/mTOR Signaling
of RMS13 Cells
To investigate the impact of oncogenic mutant variants of RAS
in RMS, we ectopically expressed NRAS12V, KRAS12V, or
HRAS12V in the RMS cell line RMS13 that harbors wild-type
RAS. Ectopic expression of mutant RAS genes was confirmed by
Western blot analysis using a pan-RAS antibody (Figure 1A). To
determine whether overexpression of mutant RAS genes affects
activation of RAS/MEK/ERK and/or PI3K/AKT/mTOR path-
ways, we assessed in parallel the phosphorylation status of key
components of these pathways. Overexpression of mutant RAS
genes resulted in increased phosphorylation of ERK or AKT
(Figures 1B,C; Figure S1 in Supplementary Material), indicating
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FIGURE 3 | Effects of oncogenic RAS genes on spontaneous cell
death of RMS13 cells. RMS13 cells expressing EV, HRAS12V, KRAS12V, or
NRAS12V were incubated for 48 h. Apoptosis was determined by analysis of
DNA fragmentation of PI-stained nuclei (A), and cell death was determined by
PI staining (B) using flow cytometry. Mean+SD of three independent
experiments performed in triplicate are shown.
that overexpression of mutant RAS genes results in increased
activation of downstream signaling pathways.
Effects of Oncogenic RAS Genes on Cell
Numbers and Clonogenic Growth of RMS13 Cells
Next, we investigated the effects ofmutantRAS genes on cell num-
bers. Ectopic expression of NRAS12V, KRAS12V, and HRAS12V
all caused a significant increase in cell numbers compared to
cells expressing empty control vector (Figure 2A). In addition,
overexpression of mutant RAS genes significantly increased cell
viability as determined by MTT assay (Figure 2B). Besides MTT
assay, which relies on mitochondrial activity and may not reliably
assess cell viability under oxidative stress, we also used crystal
violet assay as another assay to determine cell viability, which
yielded similar results (Figure 2C). In addition to these short-term
assays, we also assessed long-term effects using colony assays
to determine clonogenic survival. Of note, ectopic expression of
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FIGURE 4 | Oncogenic RAS genes rescue dual PI3K/mTOR
inhibitor-mediated cytotoxicity. RMS13 cells expressing EV, HRAS12V,
KRAS12V, or NRAS12V were treated for 24–72 h (A,B) or 48 h (C) with
indicated concentrations of Doxorubicin (A), Etoposide (B), or PI103 (C).
Cell viability was determined by MTT assay and cell density by crystal violet
assay; results are expressed as percentage of untreated cells. Mean+SD of
three independent experiments performed in triplicate are shown; *p<0.05;
**p<0.01.
NRAS12V, KRAS12V, and HRAS12V resulted in a significant
increase in colony numbers compared to cells transduced with
empty control vector (Figure 2D). This set of experiments shows
that overexpression of mutant RAS genes increases cell numbers
and clonogenic survival of RMS13 cells.
Effects of Oncogenic RAS Genes on
Spontaneous Cell Death of RMS13 Cells
Since RAS has been implicated in the regulation of cell death in
addition to cell growth, we also determined spontaneous cell death
of untreated RMS13 cells in the absence of any cytotoxic stimulus.
Analysis of DNA fragmentation, used as a characteristic marker
of apoptotic cell death, showed no significant changes in DNA
fragmentation upon overexpression of NRAS12V, KRAS12V, or
HRAS12V compared to cells expressing empty control vector
(Figure 3A). Similarly, overexpression of mutant RAS genes did
not result in enhanced plasmamembrane permeability as assessed
by PI staining that was used as a marker of non-apoptotic cell
death (Figure 3B). Based on these results, we conclude that
ectopic expression of NRAS12V, KRAS12V, and HRAS12V does
not increase spontaneous cell death of RMS13 cells.
Oncogenic RAS Genes Rescue Dual PI3K/mTOR
Inhibitor-Mediated Cytotoxicity
Next, we investigated the question whether oncogenic RAS
mutants affect the sensitivity of RMS13 cells toward anticancer
agents. To this end, we tested the cytotoxicity of Doxoru-
bicin or Etoposide, two chemotherapeutic drugs that are com-
monly used in clinical protocols for the treatment of RMS.
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Dose response and kinetic analysis showed that Doxoru-
bicin and Etoposide reduced cell viability of RMS13 cells in
a concentration- and time-dependent manner irrespective of
whether or not NRAS12V, KRAS12V, or HRAS12V were ectopi-
cally expressed (Figures 4A,B). By contrast, overexpression of
NRAS12V, KRAS12V, or HRAS12V significantly rescued loss
of cell viability or cell density upon treatment with the dual
PI3K/mTOR inhibitor PI103 (Figure 4C).
Oncogenic RAS Genes Protect Against Oxidative
Stress Stimuli
Since oncogenic RAS has been implicated in regulating the sen-
sitivity of cancer cells to oxidative stress (10), we extended our
study to several agents that interfere with antioxidative defense
mechanisms and thereby increase reactive oxygen species (ROS)
levels. Interestingly, we found that overexpression of NRAS12V,
KRAS12V, or HRAS12V significantly protected RMS13 cells
against loss of cell viability and reduction of cell density upon
treatment with Auranofin (Figure 5A), an inhibitor of thiore-
doxin reductase (13). Also, RMS13 cells engineered to overex-
press NRAS12V, KRAS12V, or HRAS12V were significantly more
resistant to RSL3 (Figure 5B), a pharmacological inhibitor of
glutathione (GSH) peroxidase 4 (GPX4) (14). GPX4 is the only
GPX that specifically reduces hydroperoxides within membranes
(15). In addition, RMS13 cells exhibiting oncogenic RAS mutants
were significantly less susceptible against Erastin (Figure 5C).
Erastin is an inhibitor of system xc , a cysteine/glutamate amino
acid transporter at the plasma membrane (10), and inhibits
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FIGURE 5 | Oncogenic RAS genes protect against oxidative
stress stimuli. RMS13 cells expressing EV, HRAS12V, KRAS12V, or
NRAS12V were treated for 48 h with indicated concentrations of
Auranofin (A), RSL3 (B), or Erastin (C). Cell viability was determined by
MTT assay and cell density by crystal violet assay; results are
expressed as percentage of untreated cells. Mean+SD of three
independent experiments performed in triplicate are shown; *p<0.05;
**p<0.01; ***p<0.001.
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GSH synthesis by blocking cysteine uptake. Together, this set of
experiments demonstrates that oncogenic RAS mutants protect
RMS13 cells against several oxidative stress stimuli.
Oncogenic RAS Genes Protect Against
Ferroptotic Cell Death
We noted that oncogenic RAS mutants conferred protection
against both RSL3 and Erastin, which either directly (i.e., RSL3)
or indirectly through GSH depletion (i.e., Erastin) inhibit GPX4
(14). Since GPX4 has recently been identified as an essential reg-
ulator of ferroptosis (14), an iron-dependent non-apoptotic mode
of cell death (16), we asked whether RSL3 and Erastin trigger
ferroptotic cell death in RMS13 cells. To address this question,
we used Ferrostatin-1, which has been described to block ferrop-
tosis (10). Indeed, addition of Ferrostatin-1 significantly reduced
RSL3- or Erastin-induced loss of cell viability (Figures 6A,B). To
further test whether RSL3 and Erastin engage a non-apoptotic
form of cell death, we assessed in parallel plasma membrane per-
meability using PI-staining and DNA fragmentation as markers
of non-apoptotic and apoptotic cell death, respectively. Notably,
treatment with RSL3 or Erastin caused a significant increase in
plasma membrane permeability as reflected by increased PI pos-
itivity (Figures 6C,D), whereas only a minor increase in the rate
of DNA fragmentation was observed (Figures 6E,F), consistent
with a non-apoptotic mode of cell death. Together, this set of
experiments indicates that RSL3 and Erastin trigger ferroptotic
cell death in RMS13 cells.
Discussion
In the present study, we investigated the role of oncogenic RAS
genes in the regulation of cell death of RMS13 cells. A key
finding of our study is the increased resistance to oxidative
stress that is conferred by ectopic expression of oncogenic RAS
mutants. RMS13 cells engineered to expressNRAS12V, KRAS12V,
or HRAS12V proved to be significantly less vulnerable to several
redox-targeting agents that inhibit antioxidative defense systems
responsible for ROS detoxification. This increased resistance to
oxidative stress occurs upon inhibition of distinct antioxidative
defense pathways, including the GSH system (that is inhibited
by Erastin and RSL3) as well as the thioredoxin system (that is
inhibited by Auranofin), emphasizing the general relevance of
this finding. Interestingly, this form of oxidative stress-induced
cell death turned out to be ferroptosis, a recently defined iron-
dependent form of programed cell death involving ROS pro-
duction (16). Our rescue experiments showing that Ferrostatin-1
confers protection against Erastin- or RSL3-induced cytotoxicity
underscores that these compounds trigger ferroptotic cell death in
RMS13 cells that is attenuated by oncogenic RAS mutants.
Of note, our key finding showing that the RAS mutation status
imparts resistance toward treatment with ferroptosis-inducing
compounds such as Erastin and RSL3 is in line with recent
evidence documenting that the RAS mutation status does not
predict sensitivity to Erastin (14). A large analysis of more than
a hundred of different cancer cell lines recently documented no
selective lethality of Erastin in RAS-mutated cancer cell lines
over RAS wild-type counterparts (14). This comprehensive study
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FIGURE 6 | Oncogenic RAS genes protect against ferroptotic cell
death. (A,B) RMS13 cells expressing EV were treated for 48 h with indicated
concentrations of RSL3 (A) or Erastin (B) in the presence or absence of 5µM
Ferrostatin-1. Cell viability was determined by MTT assay; results are
expressed as percentage of untreated cells. Mean+SD of three independent
experiments performed in triplicate are shown; *p<0.05; **p<0.01;
***p<0.001. (C–F) RMS13 cells expressing EV were treated for 48 h with
indicated concentrations of RSL3 or Erastin. Apoptosis was determined by
analysis of DNA fragmentation of PI-stained nuclei (C,D) and cell death was
determined by PI staining (E,F) using flow cytometry. Mean+SD of three
independent experiments performed in triplicate are shown; *p<0.05;
**p<0.01; ***p<0.001.
indicates that oncogenic RAS does not confer sensitivity to Erastin
across cancers. By comparison, Erastin has been reported to
exhibit greater lethality in human tumor cells harboringmutations
in the oncogenesHRAS,KRAS, or BRAF (17) as well as in an indi-
vidual genetic context using isogenic cell lines with and without
oncogenic RAS genes (10). Thus, there are likely to be found other
more dominant determinants of sensitivity toward Erastin than
RASmutations when analyzing sensitivity across diverse contexts.
In addition to redox-targeting agents, oncogenic RAS mutants
also conferred resistance to the dual PI3K/mTOR inhibitor
PI103, while they did not alter the response to DNA-damaging
chemotherapeutics such as Etoposide and Doxorubicin. This sug-
gests that oncogenic RAS selectively modulates cell death path-
ways in response to cytotoxic stimuli in RMS13 cells.
Oncogenic forms of RAS have previously been implicated in
the control of both proliferation and cell death of cancer cells
(9). Consistent with the well-documented role of oncogenic RAS
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to drive cell cycle progression and clonogenic growth, RMS13
cells harboring NRAS12V, KRAS12V, or HRAS12V exhibited a
significant increase in proliferation and colony formation as com-
pared to cells with wild-type RAS.While oncogenic RAS has been
described to also promote cell death under certain circumstances
(9), we found no evidence of increased spontaneous cell death in
the absence of lethal insults in RMS13 cells, neither apoptotic nor
non-apoptotic cell death.
Several genomic studies of RMS samples have revealed a high
rate of recurrent mutations in the RAS pathway, which is associ-
ated with intermediate and high-risk disease (3). This underscores
that RAS signaling is a clinically relevant oncogenic pathway in
RMS. Our present study contributes to a better understanding
of the biology of oncogenic RAS in RMS. While RAS remains
one of the most elusive genes to target directly, RAS mutant
cells have been shown to depend on a number of oncogenic
signaling pathways that arise as a means of adaptation to RAS-
driven intracellular stresses and represent unique vulnerabilities
of mutant RAS cancers (18). In RMS, concomitant inhibition of
the RAS/MEK/ERK and PI3K/AKT/mTOR pathways has recently
been demonstrated in two independent studies to synergistically
trigger apoptosis and to inhibit tumor growth in vivo (19, 20).
Thus, therapeutic targeting of RAS effector pathways and the
search for synthetic lethal interactors of mutant RAS may offer
exiting opportunities for new therapeutic directions.
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